On May 7, 2025, Asit Parikh, a Director at Phathom Pharmaceuticals Inc (PHAT, Financial), purchased 10,000 shares of the company. Following this transaction, the insider now holds a total of 95,500 shares. The purchase was documented in a SEC Filing. Phathom Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases. The company's mission is to address unmet needs in the gastrointestinal space with innovative therapies. The recent acquisition by the insider is part of a broader trend observed over the past year, where the insider has purchased a total of 30,000 shares and has not sold any shares. This activity is set against a backdrop of 4 insider buys and 9 insider sells within the company over the same period. Shares of Phathom Pharmaceuticals Inc were trading at $2.5 each on the day of the insider's purchase, resulting in a market cap of $159.874 million for the company.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.